改变肺癌轨迹(中)

We made a very strong case to leadership at Johnson & Johnson that there's no disease that's a bigger unmet need right now worldwide than lung cancer, in terms of a holistic cross-sector solution.

我们向强生公司的领导层强调，就跨部门的整体解决方案而言，目前全世界没有比肺癌更需要解决的疾病了。

So you were kind of whispering in their ear and saying, Hey, do lung cancer first?

所以你在他们的耳边低语，嘿，肺癌是首要需要解决的疾病？

I think I was more than whispering.

我想我不仅仅是在窃窃私语。

I may have been yelling a little bit.

我可能是在大喊着宣传。

At the time, as a physician on the front lines, I was seeing day in and day out what this disease was doing to my patients, to their families, to society, to the world — the cost of the disease.

当时，作为一名第一线的医生，我日复一日地看到这种疾病对我的患者、患者的家人、社会和世界造成了什么--疾病的代价。

And I felt this was a disease, more than any other, in need of a new approach — transformative innovation.

我觉得这是一种疾病，比任何其他疾病都更需要一种新的变革创新的方法。

I couldn't imagine any company in the world that could do it the way J&J could, given that they had medical devices and pharmaceuticals under the same umbrella.

我无法想象世界上还有哪家公司能像强生那样做到这一点，因为他们的医疗设备和药品都在同一个组织下。

Leadership listened.

领导层听到了我的意见。

With support from Dr. Bill Hait, who was Global Head of External Innovation at the time, the Lung Cancer Initiative at Johnson & Johnson was formed in 2018 and Avi became the Global Head.

在时任外部创新全球负责人的比尔·海特博士的支持下，强生公司于2018年成立了肺癌倡议小组，阿维成为全球负责人。

Since then, he’s assembled a diverse team from inside and outside the company.

从那时起，他从公司内部和外部组建了一个多元化的团队。

I call it the dream team that we've been able to put together.

我称之为我们能够组建的梦之队。

And that's because I think it's relatively unique to have deep, deep expertise in medical devices alongside very deep expertise in pharmaceuticals, all under one roof.

这是因为我认为，强生拥有深厚的医疗设备专业知识和非常深厚的制药专业知识，所有都在一个体系下，这是相对独有的。

So what that allows us to do is really put together a multidisciplinary group of scientists, clinicians, all the support staff, that one would need to go out and create unique solutions that were previously unimagined for this disease.

因此，我们真正能够做的是组建一个由科学家、临床医生和所有支持人员组成的多学科小组，这个小组需要走出去，创造出以前无法想象的针对这种疾病的独有的解决方案。

In the four years since the Lung Cancer Initiative was formed, Avi’s team has been working to address the two biggest unmet needs along the patient journey.

自肺癌倡议成立以来的四年里，阿维的团队一直在努力解决患者患病过程中两个最大的未得到满足的需求。

Think about a robotic bronchoscope that could make it easier to tell if a growth or spot on someone’s lung is cancerous or not.

想想自动支气管窥镜，这种窥镜可以使判断某人肺部的某个肿块或斑点是否是癌症变得更容易。

It’s an endoscope that goes through your mouth or nose that's robotically controlled and can snake its way out in a relatively non-invasive way, all the way out to previously unreachable parts of your lung.

这是一种通过嘴巴或鼻子的内窥镜，可以自动控制，可以以相对非侵入性的方式蜿蜒前进，一直延伸到以前无法触及的肺部。

Once this bronchoscope reaches that distant part of the lung, it can take a small sample of the growth to test for cancer cells.

一旦支气管窥镜到达肺的远处，就可以采集一小块生长样本来检测癌细胞。

But there’s more to the vision of the Lung Cancer Initiative at Johnson & Johnson.

但强生公司肺癌倡议的愿景不止如此。

We are excited to use this robotic bronchoscope to not only go out and diagnose lung cancer earlier, which was that first unmet need, but in that procedure also to treat the lung cancer by injecting a drug or energy directly into it through the bronchoscope.

我们感到兴奋的是使用这种自动支气管镜不仅可以进入肺部，更早地诊断出肺癌，这是第一个未得到满足的需求，而且在这个过程中还可以通过支气管镜直接向肺部注入药物来治疗肺癌。

And having a less invasive, more precise way of treating and more effectively treating that disease.

这种方法侵入性更小，能更精确地、更有效地治疗这种疾病。

It’s very exciting to hear that one day in the future you may be able to treat within a tumor, known as intratumoral therapy, and we hope Dr. Spira will come back again to tell us about additional progress made.

听到在未来的某一天你可能能够在肿瘤内进行治疗，这是非常令人兴奋的，我们希望斯皮拉博士会再次回来告诉我们进一步的进展。